2 results
Approved WMOCompleted
The study will investigate the safety and efficacy of emicizumab in patients with hemophilia A with inhibitors against FVIII.
Approved WMOCompleted
To demontrate improvement of progression-free survival (PFS) and/or overall survival (OS) with M7824 compared with pembrolizumab in first-line participants with advanced NSCLC with high PD-L1 tumor expression.